Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

vestigator for the Phase 1 and Phase 1b/2 clinical trials of voreloxin in AML. "Voreloxin appears to be a promising new drug for the treatment of AML and I look forward to the results of continued clinical investigation."

Copies of these poster presentations are available at http://www.sunesis.com.

About Voreloxin

Voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer, voreloxin has shown objective responses and been generally well-tolerated.

Conference Call Information

Sunesis management will host a conference call on Tuesday, December 9, 2008, at 11:00 a.m. ET / 8:00 a.m. PT to discuss the voreloxin and SNS-032 clinical data presented at ASH. Individual and institutional investors can access the call via 1-877-856-1956 (U.S. and Canada) or +1-719-325-4805 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company's website until December 23, 2008.

About Acute Myeloid Leukemia

AML is a rapid
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014 As medical device manufacturers ... Labeling) markup language standard, content teams have a greater ... to work with the standard. Starting January 2015, Data ... webinars on the benefits and the critical aspects of ... be facilitated by Howard Shatz , DCL,s SPL ...
(Date:12/15/2014)... , Dec. 15, 2014   DaVita ... one of the nation,s largest and most innovative ... its business units, DaVita Clinical Research  (DCR) and  ... to further expand its extensive clinical research and ... kidney disease (CKD) and end-stage renal disease (ESRD), ...
(Date:12/15/2014)... , December 15, 2014 Heptares ... company, is pleased to announce the grant of multiple ... relating to its GPCR-focused drug discovery platform. The ... the global patent estate covering Heptares, technologies and products ... of patents recently granted by the US Patent Office ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... BASIS Science, Inc. ( www.mybasis.com ) the creators of the ... B1 band, will be demoing at the 2012 International CES ... for the first time. The dashboard has been designed as ... health and wellness. "We have designed the Basis ...
... Valley Technologies, Inc. (LVT) is pleased to announce ... the U.S. Food and Drug Administration (FDA).  On ... with no Form 483 observations and no discussion ... relating to cGMP (current Good Manufacturing Practices).  Additionally, ...
Cached Medicine Technology:BASIS Science to Demo Basis Band at 2012 International CES; Reveals Design of Web Dashboard 2
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Expectant parents should leave prenatal ... Administration recommends. Use of ultrasound imaging and heartbeat ... entirely risk-free, the agency warns. "Although there ... to ultrasound imaging and heartbeat monitors, prudent use of ... Shahram Vaezy, an FDA biomedical engineer, said in an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3
... UNITED™ Campaign , ... Alexandria, V.A. ... most experienced independent social media-oriented public relations firm, signed a ... social media strategy for the organization,s LIVE UNITED™ campaign. The ...
... Stock, the leading independent supplier of royalty free stock photography, images ... of rights managed editorial images.,Included in the new collections is Heritage ... the British Library, Guildhall and the British Museum. Most of the ... ...
... Westchester, Ill. A study in the Oct. 1 issue ... increased rate of follicle stimulating hormone (FSH) change that ... duration but poor subjective sleep quality. , Findings ... participants indicate that postmenopausal women had deeper sleep and ...
... MD (Oct. 1, 2008) Obese patients with a ... the weight loss drug sibutramine and undergoing behavioral therapy ... new study in Gastroenterology , the official journal ... The obesity epidemic continues to be an increasingly global ...
... fever, the often seasonal allergy that affects between 10 ... controlled through a course of patient-adjusted dosing, according to ... Otolaryngology Head and Neck Surgery. , ... clinically as allergic rhinitis, was observed in 69 patients, ...
... part of an Asian-white ,couple face an increased risk ... both partners are white, according to a new study ... ,School of Medicine. , The researchers also found that Asian ... white women with Asian or white partners to have ...
Cached Medicine News:Health News:United Way of America Partners with Livingston Communications to Develop Social Media Strategy 2Health News:Reflex Stock Launches Exciting New Editorial Image Collections to the Worldwide Publishing Industry 2Health News:Changes in sex steroids associated with menopause 2Health News:Changes in sex steroids associated with menopause 3Health News:Genes influence effectiveness of weight-loss drug 2Health News:Genes influence effectiveness of weight-loss drug 3Health News:Hay fever may be best treated with self-adjusted dosing 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 3